The Upjohn Co.

Dale A Stringfellow

Patricia E Fast

Wendell Wierenga

Harvey I Skulnick

A method for altering the immunoregulatory system of humans and animals by administering a compound of the formula: ##STR1## wherein X.sub.3 is equal to X, X.sub.4, or X.sub.5 wherein X.sub.4 is fluoro, chloro, bromo or iodo, and X.sub.5 is mono-, di- or trihalomethyl, mono-, di or trifluoroethyl, perfluoropropyl, and wherein X is alkyl of from 1 to 3 carbon atoms, inclusive, 2-propynyl and 2-propenyl, and X.sub.1 is as defined in the specification.

Method for treating cancer with 6-aryl pyrimidine compounds

6-Aryl pyrimidinol compounds, also can be named 6-aryl pyrimidinone or 6-aryl-isocytosine novel compounds, also novel and old compounds useful for treating viral infections and inducing interferon production. Dosage forms and method of treatment are disclosed.

6-aryl pyrimidine compounds and method for treating viral infections and

A method for treating bacterial or protozoal humans and animals by administering a 6-aryl pyrimidine compound or a salt thereof in association with a pharmaceutical carrier.

Method for treating bacterial and protozoal infections

A method for treating rejection of organ or skin grafts in humans and animals by administering 2-amino-6-aryl-5-substituted pyrimidines.

Method for treating rejection of organ or skin grafts with 6-aryl

A method for treating aplastic anemia by systemic administration of a 6-aryl pyrimidine compound or a pharmaceutically acceptable salt thereof in association with a pharmaceutical carrier to a human or animal having aplastic anemia.

6-aryl pyrimidines for treating aplastic anemia

A method for altering the immunoregulatory system of humans and animals by administering a 6 aryl pyrimidine compound or a salt thereof in association with a pharmaceutical carrier.

Method for immunoregulation with 6-aryl pyrimidine compounds

The present invention provides a method for treatment of hyporeactivity to interferon induction in interferon producing animals or animal cells which comprises administering a hyporeactive interferon stimulating prostaglandin (HIS-PG) to an interferon producing animal or animal cells having a hyporeactive (decreased) interferon response. Hyporeactive interferon stimulating prostaglandins (HIS-PG) refers to those prostaglandin-type compounds which are useful in alleviating the decreased ability of interferon producing animals or animal cells to produce interferon following administration of repeated doses of an interferon inducer or as a consequence of viral infection or neoplasia.

Growing community of inventors

Kalamazoo, MI, United States of America

Dale A Stringfellow